Szabolcs Kéri1, Csilla Szabó2, Oguz Kelemen3. 1. University of Szeged, Faculty of Medicine, Department of Physiology, Dóm square 10, H6720 Szeged, Hungary; Nyírő Gyula Hospital National Institute of Psychiatry and Addictions, Budapest, Hungary; Budapest University of Technology and Economics, Department of Cognitive Science, Budapest, Hungary. Electronic address: keri.szabolcs.gyula@med.u-szeged.hu. 2. Nyírő Gyula Hospital National Institute of Psychiatry and Addictions, Budapest, Hungary. 3. Bács-Kiskun County Hospital, Psychiatry Center, Kecskemét, Hungary.
Abstract
BACKGROUND: Results from convergent genomics indicated new peripheral biomarkers for mood states. We sought to investigate the clinical utility of the BioM-10 Mood Panel, a peripheral biomarker set of low vs. high mood states, in the diagnosis of major depressive episode and to monitor the effectiveness of cognitive-behavioral therapy (CBT). METHOD: 44 patients with a first episode of major depression and 30 healthy control subjects participated in the study. The BioM-10 panel׳s gene expression profile was measured from whole peripheral blood with the Affymetrix Human Genome U133 Plus 2.0 Gene Chips, focusing on 10 top genes related to high mood states (MBP, EDG2, FZD3, ATXN1, and EDNRB) and low mood states (FGFR1, MAG, PMP22, UGT8, and ERBB3). We studied gene expression before and after CBT. RESULTS: The BioM-10 prediction score discriminated patients and controls with high sensitivity (84%) and specificity (90%). There was an increase in the BioM-10 prediction score after CBT relative to the pretreatment value. Clinical improvement was associated with higher prediction scores reflecting a greater ratio of high mood markers relative to low mood markers. LIMITATIONS: Sample size was small for a genome-wide microarray study. Convergent genomic studies have not been conducted in major depressive disorder. More evidence is needed from patients with severe, recurrent, and chronic forms of depression. CONCLUSIONS: The BioM-10 panel is a promising tool as a biomarker setup for the evaluation of low and high mood states across diagnostic categories. The panel includes genes related to growth factor pathways and myelination, which may provide new insights into the pathophysiology of mood dysregulation.
BACKGROUND: Results from convergent genomics indicated new peripheral biomarkers for mood states. We sought to investigate the clinical utility of the BioM-10 Mood Panel, a peripheral biomarker set of low vs. high mood states, in the diagnosis of major depressive episode and to monitor the effectiveness of cognitive-behavioral therapy (CBT). METHOD: 44 patients with a first episode of major depression and 30 healthy control subjects participated in the study. The BioM-10 panel׳s gene expression profile was measured from whole peripheral blood with the Affymetrix Human Genome U133 Plus 2.0 Gene Chips, focusing on 10 top genes related to high mood states (MBP, EDG2, FZD3, ATXN1, and EDNRB) and low mood states (FGFR1, MAG, PMP22, UGT8, and ERBB3). We studied gene expression before and after CBT. RESULTS: The BioM-10 prediction score discriminated patients and controls with high sensitivity (84%) and specificity (90%). There was an increase in the BioM-10 prediction score after CBT relative to the pretreatment value. Clinical improvement was associated with higher prediction scores reflecting a greater ratio of high mood markers relative to low mood markers. LIMITATIONS: Sample size was small for a genome-wide microarray study. Convergent genomic studies have not been conducted in major depressive disorder. More evidence is needed from patients with severe, recurrent, and chronic forms of depression. CONCLUSIONS: The BioM-10 panel is a promising tool as a biomarker setup for the evaluation of low and high mood states across diagnostic categories. The panel includes genes related to growth factor pathways and myelination, which may provide new insights into the pathophysiology of mood dysregulation.
Authors: David J Miklowitz; Larissa C Portnoff; Casey C Armstrong; Danielle Keenan-Miller; Elizabeth C Breen; Keely A Muscatell; Naomi I Eisenberger; Michael R Irwin Journal: Psychiatry Res Date: 2016-05-07 Impact factor: 3.222
Authors: Stefan Wuchty; Amanda J Myers; Manuel Ramirez-Restrepo; Matthew Huentelman; Ryan Richolt; Felicia Gould; Philip D Harvey; Vasiliki Michopolous; Jennifer S Steven; Aliza P Wingo; Adriana Lori; Jessica L Maples-Keller; Alex O Rothbaum; Tanja Jovanovic; Barbara O Rothbaum; Kerry J Ressler; Charles B Nemeroff Journal: Mol Psychiatry Date: 2021-05-07 Impact factor: 15.992
Authors: Roman Dario Moreno-Fernandez; Sara Tabbai; Estela Castilla-Ortega; Margarita Perez-Martin; Guillermo Estivill-Torrus; Fernando Rodriguez de Fonseca; Luis Javier Santin; Carmen Pedraza Journal: Curr Neuropharmacol Date: 2018-03-05 Impact factor: 7.363
Authors: Z Kaminsky; H C Wilcox; W W Eaton; K Van Eck; V Kilaru; T Jovanovic; T Klengel; B Bradley; E B Binder; K J Ressler; A K Smith Journal: Transl Psychiatry Date: 2015-08-25 Impact factor: 6.222